Small molecule therapy for managing moderate to severe psoriatic arthritis

Costa, Luisa; Puente, Antonio Del; Peluso, Rosario; Tasso, Marco; Caso, Paolo; Chimenti, Maria Sole; Sabbatino, Vincenzo; Girolimetto, Nicolò; Benigno, Carolina; Bertolini, Nicoletta; Puente, Aurora Del; Perricone, Roberto; Scarpa, Raffaele; Caso, Francesco

doi:10.1080/14656566.2017.1378343

Cited by 40 publications

(25 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, it should be noted that IL-17 has been shown to play a key role in other forms of arthritis, such as Psoriatic Arthritis (PsA), in which the induction of IL-17 cytokines axis (IL-17A, IL-17F and IL-22) promotes intra-and/or peri-articular inflammation [71,72,73]. To better understand this previous observation and viewing the coin from other side a flow cytometry bioassay was carried out on peripheral blood to evaluate the balance Treg/Th17 after MSU crystals induction and IL-17Ab treatment.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation

Raucci

Iqbal

Saviano

et al. 2019

Pharmacological Research

Self Cite

View full text Add to dashboard Cite

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document. When citing, please reference the published version. Take down policy While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation

Raucci

Iqbal

Saviano

et al. 2019

Pharmacological Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…See Table 1 for summary of indication and oral administration for jak inhibitors. Jak 1/2 blockade represents an attractive cellular target because Jak 3 but not Jak 1/2 blockade induces natural killer cell depletion and systemic side effects that can promote immunosuppression (79)(80)(81)(82). Ruxolitinib has demonstrated potent inhibition of reservoir establishment, maintenance and expansion in primary T cells and macrophages in vitro and ex vivo (7), and demonstrated reduction in immune activation markers associated with HIV-1 persistence including CCR5, HLA-DR, CD38, CD25, Ki67, and PD-1.…”

Section: Jak Inhibitorsmentioning

confidence: 99%

Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV

et al. 2019

View full text Add to dashboard Cite

Recently, a second individual (the "London patient") with HIV-1 infection and concomitant leukemia was cured of both diseases by a conditioning myeloablative regimen followed by transplantation of stem cells bearing the homozygous CCR5 32 mutation. The substantial risks and cost associated with this procedure render it unfeasible on a large scale. This strategy also indicates that a common pathway toward a cure for both HIV and cancer may exist. Successful approaches to curing both diseases should ideally possess three components, i.e., (1) direct targeting of pathological cells (neoplastic cells in cancer and the HIV-infected reservoir cells), (2) subsequent impediment to reconstitution of the pool of pathological cells and (3) sustained, immunologic control of the disease (both diseases are characterized by detrimental immune hyper-activation that hinders successful establishment of immunity). In this review, we explore medications that are either investigational or FDA-approved anticancer treatments that may be employed to achieve the goal of curing HIV-1. These include: thioredoxin reductase inhibitors (phases 1-3), immune checkpoint inhibitors (phases 1, 3), Jak inhibitors (FDA approved for arthritis and multiple cancer indications, summarized in Table 1). Of note, some of these medications such as arsenic trioxide and Jak inhibitors may also reversibly down regulate CCR5 expression on CD4 + T-cells, thus escaping the ethical issues of inducing or transferring mutations in CCR5 that are presently the subject of interest as it relates to HIV-1 cure strategies.

show abstract

“…1 zu entnehmen. Bei PsA spiegelt sich die Erweiterung der therapeutischen Möglichkeiten in stärkerem Ausmaß wieder als bei SpA, Anti-IL17-Präparate sind ebenso wie anti-IL12/23 Präparate und PDE-4 Hemmer sind offenbar bereits fester Bestandteil des therapeutischen Armamentariums [22][23].…”

Section: Psoriasis-arthritisunclassified

Biologika-Therapien in Österreich. Daten aus dem Österreichischen Biologika-Register BioReg

et al. 2018

View full text Add to dashboard Cite

ZusammenfassungIn Österreich wurde vergleichsweise spät im Jahre 2009, das „Biologikaregister für entzündlich rheumatische Erkrankungen e. V.“, kurz BioReg, gegründet, mit den auch in anderen Ländern verfolgten Zielen, jene PatientInnen, die mit Biologika behandelt werden, hinsichtlich Tolerabilität und Effektivität zu dokumentieren. Aus dem Vereinsmodell ergibt sich die Freiwilligkeit der Teilnahme von Verschreibern, vergleichbar dem deutschen RABBIT Register. Mit Ende Mai 2017 waren insgesamt 2132 PatientInnen in die Datenbank eingeschlossen, davon waren 1157 PatientInnen mit Rheumatoider Arthritis (RA), 497 mit Spondylitis ankylosans (SpA), 401 mit Arthritis psoriatica (PsA) und 77 PatientInnen mit sonstigen rheumatischen Erkrankungen (SERE). Österreichs Rheumatologen initiieren – im Vergleich zu europäischen Kollegen – eine bDMARD-Therapie bereits bei RA Patienten mit hoch moderater Krankheitsaktivität. Der Behinderungsgrad der Patienten unter Biologika-Therapie kann insgesamt niedrig gehalten werden, was natürlich auch für den Erhalt der Berufsfähigkeit von Bedeutung ist. Außergewöhnliche Nebenwirkungen wurden bisher nicht beobachtet, die in BioReg aufgetretenen Nebenwirkungen entsprechen den bereits aus Studien bekannten. Die Häufigkeit der Anwendung der einzelnen Präparate ist durchaus mit der in Deutschland vergleichbar, auch die Retentionsraten sind nicht wesentlich unterschiedlich. Register, wie auch BioReg, zeigen den „heimlichen“ Normalfall der Behandlung von Patientinnen und Patienten mit entzündlich rheumatischen Erkrankungen und liefern damit einen wesentlichen Beitrag zur Qualitätssicherung.

show abstract

Small molecule therapy for managing moderate to severe psoriatic arthritis

Cited by 40 publications

References 131 publications

IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation

IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation

Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV

Biologika-Therapien in Österreich. Daten aus dem Österreichischen Biologika-Register BioReg

Contact Info

Product

Resources

About